GlassScriptPhysician profile
Ellis H Tobin
NPI 1306922166
$5,920.15
in general payments reported to CMS, 2019-2025
24 companies · $1,023 in 2025
The $1,023 reported for 2025 was more than what 79% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,212 · 2020: $902 · 2021: $326 · 2022: $545 · 2023: $777 · 2024: $1,135 · 2025: $1,023.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,702 · Education: $233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,701.62 |
| Education | $232.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,615.32 | 2019-2025 | Dovato, Rukobia, Apretude |
| Merck Sharp & Dohme LLC | $1,036.36 | 2019-2025 | Zerbaxa, Delstrigo, Recarbrio |
| Abbvie INC. | $597.47 | 2021-2025 | Avycaz, Dalvance, Teflaro |
| Janssen Biotech, INC. | $419.61 | 2019-2023 | Symtuza |
| Astellas Pharma US INC | $383.88 | 2019-2025 | Cresemba |
| Theratechnologies INC. | $302.93 | 2020-2025 | Trogarzo, Egrifta, Egrifta Sv |
| Allergan, INC. | $264.83 | 2019-2020 | |
| Shionogi INC | $214.67 | 2021-2025 | Fetroja |
| Janssen Products, LP | $183.99 | 2022-2023 | Symtuza |
| Melinta Therapeutics, LLC | $131.49 | 2019-2024 | Kimyrsa, Vabomere, Rezzayo |
| Paratek Pharmaceuticals, INC. | $118.81 | 2020-2023 | Nuzyra |
| Insmed, INC. | $110.25 | 2019 | |
| Ferring Pharmaceuticals INC. | $90.17 | 2022-2025 | Rebyota |
| Emd Serono, INC. | $85.83 | 2019-2024 | |
| Gilead Sciences, INC. | $83.46 | 2019-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nabriva Therapeutics, Plc | $76.64 | 2020 | |
| Janssen Scientific Affairs, LLC | $57.48 | 2023 | Symtuza |
| Electromed, INC. | $31.46 | 2024 | Smartvest |
| Sanofi Pasteur INC. | $29.60 | 2025 | |
| La Jolla Pharmaceutical Company | $28.21 | 2024 | Xacduro |
| Tetraphase Pharmaceuticals, INC. | $17.20 | 2019 | |
| Vyera Pharmaceuticals, LLC | $16.02 | 2019 | |
| Glaxosmithkline, LLC. | $12.76 | 2021 | |
| Pfizer INC. | $11.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellis Tobin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.